HK1215950A1 - 異源二聚免疫球蛋白的純化 - Google Patents

異源二聚免疫球蛋白的純化

Info

Publication number
HK1215950A1
HK1215950A1 HK16103843.5A HK16103843A HK1215950A1 HK 1215950 A1 HK1215950 A1 HK 1215950A1 HK 16103843 A HK16103843 A HK 16103843A HK 1215950 A1 HK1215950 A1 HK 1215950A1
Authority
HK
Hong Kong
Prior art keywords
hetero
purification
dimeric immunoglobulins
dimeric
immunoglobulins
Prior art date
Application number
HK16103843.5A
Other languages
English (en)
Chinese (zh)
Inventor
斯坦尼斯拉斯‧布蘭
法布里齊奧‧康珀
羅曼‧奧利耶
保羅‧瓦斯曼
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of HK1215950A1 publication Critical patent/HK1215950A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK16103843.5A 2012-09-25 2016-04-05 異源二聚免疫球蛋白的純化 HK1215950A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705278P 2012-09-25 2012-09-25
PCT/EP2013/069989 WO2014049003A1 (en) 2012-09-25 2013-09-25 Purification of hetero-dimeric immunoglobulins

Publications (1)

Publication Number Publication Date
HK1215950A1 true HK1215950A1 (zh) 2016-09-30

Family

ID=49237223

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103843.5A HK1215950A1 (zh) 2012-09-25 2016-04-05 異源二聚免疫球蛋白的純化

Country Status (11)

Country Link
US (2) US20150239991A1 (ja)
EP (2) EP3401337A1 (ja)
JP (5) JP2015529236A (ja)
KR (1) KR20150076172A (ja)
CN (1) CN104968685A (ja)
AU (2) AU2013322710A1 (ja)
CA (2) CA3061557A1 (ja)
HK (1) HK1215950A1 (ja)
IL (2) IL237872B (ja)
IN (1) IN2015MN00139A (ja)
WO (1) WO2014049003A1 (ja)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
SG179196A1 (en) 2009-09-16 2012-04-27 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
CN103502271B (zh) 2011-02-28 2016-10-26 霍夫曼-拉罗奇有限公司 抗原结合蛋白
IN2015MN00139A (ja) * 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
WO2014177460A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
WO2015033223A2 (en) * 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
BR112016009919A2 (pt) 2013-11-04 2017-12-05 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma
EP3842455A1 (en) 2014-01-15 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with improved protein a-binding
AP2016009475A0 (en) 2014-03-28 2016-09-30 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
CN106573986A (zh) * 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
MX2017006918A (es) 2014-11-26 2018-01-25 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38.
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
WO2017074878A1 (en) 2015-10-25 2017-05-04 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
GB201602156D0 (en) * 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
RS64771B1 (sr) 2016-04-13 2023-11-30 Sanofi Sa Trispecifični i/ili trovalentni vezujući proteini
BR112018069890A2 (pt) * 2016-05-02 2019-02-05 Hoffmann La Roche polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão
IL265605B1 (en) * 2016-09-29 2024-02-01 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin structures, a pharmaceutical preparation containing them, their use and methods for their preparation
US11319378B2 (en) 2016-11-18 2022-05-03 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
PT3443006T (pt) * 2017-03-17 2023-10-26 Sanofi Sa Proteínas de ligação triespecíficas e/ou trivalentes
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CN111902720A (zh) 2018-03-21 2020-11-06 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
EP3773913A1 (en) 2018-04-11 2021-02-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
FR3080621B1 (fr) * 2018-04-26 2022-12-09 Univ Limoges Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde
CN112513074A (zh) 2018-06-22 2021-03-16 健玛保 生产两种或更多种不同抗体的受控混合物的方法
CN112789294A (zh) 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
CN113518647A (zh) 2018-10-11 2021-10-19 印希比股份有限公司 5t4单域抗体及其治疗性组合物
JP2022504822A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
EP3864044A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
JP7453219B2 (ja) 2018-10-11 2024-03-19 インヒブリックス， インコーポレイテッド Ｐｄ－１単一ドメイン抗体およびその治療用組成物
SG11202106393SA (en) 2018-12-24 2021-07-29 Sanofi Sa Pseudofab-based multispecific binding proteins
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
EP4141025A4 (en) * 2019-12-26 2024-04-24 Abl Bio Inc METHOD FOR PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES USING PROTEIN A AFFINITY CHROMATOGRAPHY
MX2022009306A (es) 2020-01-29 2022-09-26 Inhibrx Inc Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
EP4355786A1 (en) 2021-06-16 2024-04-24 Alector LLC Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
TW202405020A (zh) 2022-07-29 2024-02-01 美商阿列克特有限責任公司 轉鐵蛋白受體抗原結合域及其用途
WO2024050493A2 (en) * 2022-09-02 2024-03-07 Zoetis Services Llc Equine antibody mutants
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE122009000068I2 (de) 1994-06-03 2011-06-16 Ascenion Gmbh Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DK0826696T3 (da) 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
US8142780B2 (en) * 1998-08-20 2012-03-27 Strox Biopharmaceuticals, Llc Anti-bacterial antibodies
AU2006259298B2 (en) * 2005-06-17 2012-06-14 Wyeth Llc Methods of purifying Fc region containing proteins
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2647388A1 (en) 2007-02-16 2013-10-09 Merrimack Pharmaceuticals, Inc. Antibodies Against ERBB3 and Uses Thereof
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
PL2356153T3 (pl) * 2008-10-01 2016-11-30 Swoiste międzygatunkowo dwuswoiste przeciwciało jednołańcuchowe PSMAXCD3
CA2746330C (en) 2008-12-23 2017-08-29 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
CN103833855A (zh) 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
CA2785414C (en) * 2009-12-25 2019-01-22 Tomoyuki Igawa Polypeptide modification method for purifying polypeptide multimers
WO2011131746A2 (en) * 2010-04-20 2011-10-27 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
CA2812739A1 (en) 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
US9114516B2 (en) 2011-07-21 2015-08-25 Illinois Tool Works Inc. Portable combustion gas-powered tools with combustion chamber lockout system
SI2771364T1 (sl) * 2011-10-27 2019-10-30 Genmab As Produkcija heterodimernih proteinov
EP2823422A1 (en) 2012-03-06 2015-01-14 FOSS Analytical AB Method, software and graphical user interface for forming a prediction model for chemometric analysis
ES2728301T3 (es) 2012-03-13 2019-10-23 Novimmune Sa Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
IN2015MN00139A (ja) * 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
BR112016009919A2 (pt) * 2013-11-04 2017-12-05 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma

Also Published As

Publication number Publication date
EP2900696A1 (en) 2015-08-05
IL269207A (en) 2019-11-28
CA3061557A1 (en) 2014-04-03
CN104968685A (zh) 2015-10-07
IL237872B (en) 2019-09-26
IN2015MN00139A (ja) 2015-10-16
AU2013322710A2 (en) 2015-05-07
US20150239991A1 (en) 2015-08-27
AU2018204314A1 (en) 2018-07-05
IL237872A0 (en) 2015-05-31
CA2886036A1 (en) 2014-04-03
JP2018104444A (ja) 2018-07-05
JP6856610B2 (ja) 2021-04-07
AU2018204314B2 (en) 2020-05-14
JP2015529236A (ja) 2015-10-05
EP3401337A1 (en) 2018-11-14
WO2014049003A1 (en) 2014-04-03
US20200010568A1 (en) 2020-01-09
JP2020105203A (ja) 2020-07-09
JP2022116326A (ja) 2022-08-09
AU2013322710A1 (en) 2015-04-16
IL269207B (en) 2022-02-01
JP2019073512A (ja) 2019-05-16
KR20150076172A (ko) 2015-07-06

Similar Documents

Publication Publication Date Title
IL269207B (en) Purification of immunoglobulin hetero-dimers
IL270815A (en) Immunoglobulins hetero-dimers
HRP20181897T1 (hr) Pročišćavanje iduronat-2-sulfataze
ZA201507087B (en) Selective separation of nitroso-containing compounds
SG10201510800PA (en) Purification of flaviviruses
HK1207397A1 (en) Purification of succinic acid
EP2800747A4 (en) POLYMORPHY OF PERAMPANEL
SG11201406800UA (en) Purification of air
EP2697245A4 (en) METHODS OF PURIFYING HYDROPHOBIN
DK2838850T3 (da) Oprensning af titantetrachlorid
GB201209082D0 (en) Purification method
EP2892529A4 (en) USES OF (-) - PERHEXILINE
EP3560952C0 (en) VARIANT OF BPIFB4 PROTEIN
EP2714713A4 (en) PURIFICATION OF ANTIBODIES
IL233446A0 (en) Polymorphic forms of paramphenel
GB201203494D0 (en) Hydrophobin purification
EP2814499A4 (en) PURIFICATION PROCESS
GB201105866D0 (en) This is about me